// App-Quantinova.ai

4.3 1832 : Avapritinib reduced cutaneous symptoms and mast cell (MC) burden in patients (pts) with indolent systemic mastocytosis (ISM) in the PIONEER study

Researchers

Presenter

  • Hartmann K

Principal Investigators

  • Siebenhaar F

  • Elberink HO

  • Gotlib J

  • Sabato V

  • Castells M

  • Deininger MW

  • Heaney ML

  • George TI

  • Radia DH

  • Triggiani M

  • Van Daele P

  • Deangelo DJ

  • Schmidt-Kittler O

  • Lin H

  • Morrison A

  • Mar B

  • Akin C

  • Maurer M

Medical Centers

  • University Hospital Basel, Basel, Switzerland

  • Odense University Hospital, Odense, Denmark

  • Department of Cardiothoracic Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

  • University Medical Center Groningen, Nijmegen, Netherlands

  • Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA

  • University of Antwerp/Antwerp University Hospital, Antwerp, Belgium

  • Brigham and Womens Hospital, Boston, MA, United States

  • University of Utah, Salt Lake City, Utah, United States

  • Columbia University, New York, New York, United States

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • University of Palermo, Palermo, Italy

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • Blueprint Medicines,Cambridge,United States

  • Neurology, University of Michigan, Ann Arbor, United States

Locations

  • Switzerland

  • Denmark

  • Germany

  • Netherlands

  • United States

  • Belgium

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Mastocytosis

Biomarkers

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT03731260

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved